Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
McKesson
Colorcon
Fish and Richardson
McKinsey
Merck
Citi
Accenture

Generated: December 16, 2018

DrugPatentWatch Database Preview

CUBICIN RF Drug Profile

« Back to Dashboard

Which patents cover Cubicin Rf, and when can generic versions of Cubicin Rf launch?

Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in nineteen countries.

The generic ingredient in CUBICIN RF is daptomycin. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

Summary for CUBICIN RF
Drug patent expirations by year for CUBICIN RF
Pharmacology for CUBICIN RF
Medical Subject Heading (MeSH) Categories for CUBICIN RF
Synonyms for CUBICIN RF
103060-53-3
Cidecin
CS-1857
Cubicin
Cubicin (TN)
D01080
D4229
Dapcin
Daptomicina
Daptomicina [Spanish]
DAPTOMYCIN
Daptomycin (JAN/USAN/INN)
Daptomycin for injection
Daptomycine
Daptomycine [French]
Daptomycinum
Daptomycinum [Latin]
Deptomycin
HY-B0108
LY 146032
LY-146032
LY146032
MK-3009
MolPort-046-033-485
NWQ5N31VKK
SCHEMBL13491700
UNII-NWQ5N31VKK

US Patents and Regulatory Information for CUBICIN RF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CUBICIN RF
Drugname Dosage Strength RLD Date
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for CUBICIN RF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2006 Austria ➤ Sign Up PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
C0022 France ➤ Sign Up PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
C/GB06/024 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
2006 00018 Denmark ➤ Sign Up PRODUCT NAME: DAPTOMYCIN
22/2006 Austria ➤ Sign Up PRODUCT NAME: DAPTOMYCIN
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
McKesson
Colorcon
Fish and Richardson
McKinsey
Merck
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.